Mitsubishi UFJ Trust & Banking Corp Reduces Position in DaVita Inc. $DVA

Mitsubishi UFJ Trust & Banking Corp lowered its stake in DaVita Inc. (NYSE:DVA) by 4.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 136,862 shares of the company’s stock after selling 5,984 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.19% of DaVita worth $19,496,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its position in DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. National Pension Service raised its stake in shares of DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company’s stock worth $30,000 after purchasing an additional 84 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Teacher Retirement System of Texas boosted its position in DaVita by 1.4% in the second quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after buying an additional 94 shares during the last quarter. Finally, Empirical Finance LLC increased its holdings in DaVita by 6.0% in the 1st quarter. Empirical Finance LLC now owns 2,084 shares of the company’s stock worth $319,000 after buying an additional 118 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Down 1.2%

Shares of DaVita stock opened at $121.55 on Friday. The firm has a market cap of $8.58 billion, a PE ratio of 12.52, a P/E/G ratio of 0.91 and a beta of 1.13. The business has a 50-day moving average price of $127.68 and a 200 day moving average price of $135.41. DaVita Inc. has a twelve month low of $115.39 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. TD Cowen cut their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research note on Monday, November 3rd. Zacks Research downgraded DaVita from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 30th. Barclays reduced their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Thursday. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $148.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.